Titan Biotech Limited has issued a regulatory disclosure to BSE Ltd. pursuant to Regulation 29 read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
A meeting of the Board of Directors is scheduled to be held on Thursday, November 5, 2026, at the company's registered office: 903-909, 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India.
The agenda for the board meeting includes:
- To consider and approve the unaudited standalone financial results for the second quarter and half year ended September 30, 2026.
- To consider and approve the unaudited consolidated financial results for the second quarter and half year ended September 30, 2026.
- To consider and transact any other business, if any, which may be placed before the Board with the permission of the Chairman.
In accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the securities by designated persons of the Company has been closed from Thursday, October 1, 2026. The trading window will remain closed until 48 hours after the declaration of the outcome of the board meeting scheduled for November 5, 2026.
The disclosure was signed by Charanjit Singh, Company Secretary & Compliance Officer (Membership No.: A12726), on October 31, 2026.